Please login to the form below

Not currently logged in

Janssen buys hepatitis C candidate from GSK

J&J subsidiary acquires rights to NS5A inhibitor

Janssen logo 

Johnson & Johnson's Janssen unit has bolstered its hepatitis C virus treatment portfolio with the acquisition of a phase II candidate from GlaxoSmithKline (GSK).

Janssen has taken full ownership of GSK2336805, a once-daily NS5A inhibitor that GSK had advanced into phase II testing for chronic hepatitis C infection in adults with compensated liver disease, including all stages of liver fibrosis.

The company plans to start trials combining GSK2336805 with its non-nucleoside polymerase inhibitor TMC647055 and simeprevir (TMC435) - an NS3/4A protease inhibitor developed with Sweden's Medivir.

"This addition will broaden our clinical development programme as we continue to look for new investigational interferon-free treatment combinations to combat the hepatitis C virus," said Janssen's hepatitis project head Gaston Picchio.

J&J is in a race with a number of other companies to bring an all-oral treatment regimen for hepatitis C to market in order to free patients from the need for injectable and sometimes hard-to-tolerate interferon alfa-based treatment.

Simeprevir has been submitted for regulatory approval in the US, Canada and Europe, and was approved last month in Japan, but a number of other companies are already in the latter phases of development for all-oral hepatitis C regimens.

AbbVie and Gilead Sciences are currently thought to be leading the charge on interferon-free regimens with combination therapies in phase III, although Bristol-Myers Squibb, Boehringer Ingelheim and Merck & Co have also reach the latter stages of testing with their own candidates.

The sheer scale of the hepatitis C virus market in terms of the number of people infected worldwide means it is expected to swell to more than $20bn a year once all-oral regimens hit the market.

Article by
Phil Taylor

9th October 2013

From: Research, Sales



Subscribe to our email news alerts

Featured jobs


Add my company

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

Main image2
Customers, content and change
By Dominic Tyer...
Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...